931 related articles for article (PubMed ID: 25299367)
1. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
Han S; Hwang E; Park S; Park U; Kim H; Cho W
Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
[TBL] [Abstract][Full Text] [Related]
2. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
4. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
[TBL] [Abstract][Full Text] [Related]
5. Cascade plasmapheresis as preconditioning regimen for ABO-incompatible renal transplantation: a single-center experience.
Jha PK; Tiwari AK; Bansal SB; Sethi SK; Ahlawat R; Kher V
Transfusion; 2016 Apr; 56(4):956-61. PubMed ID: 26592368
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
Sugiyama K; Hyodo Y; Aikawa A
Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
[TBL] [Abstract][Full Text] [Related]
10. Trends in ABO-incompatible kidney transplantation.
Aikawa A; Saito K; Takahashi K
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():18-22. PubMed ID: 25894122
[TBL] [Abstract][Full Text] [Related]
11. ABO-incompatible kidney transplantation: first cases in Turkey.
Tuncer M; Yücetin L; Tekin S; Demirbas A
Transplant Proc; 2012; 44(6):1703-5. PubMed ID: 22841248
[TBL] [Abstract][Full Text] [Related]
12. Successful ABO incompatible renal transplantation following rituximab and DFPP after failed immunoadsorption.
Thalgahagoda S; Webb NJ; Roberts D; Birch A; Milford DV; Tavakoli A; Shenoy M
Pediatr Transplant; 2014 May; 18(3):E74-6. PubMed ID: 24483150
[TBL] [Abstract][Full Text] [Related]
13. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
15. Initial experience with ABO-incompatible live donor renal transplantation.
Tsai MK; Wu MH; Lo SC; Lai IR; Yu SC; Yuan RH; Lee PH
J Formos Med Assoc; 2006 Sep; 105(9):775-9. PubMed ID: 16959628
[TBL] [Abstract][Full Text] [Related]
16. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
[TBL] [Abstract][Full Text] [Related]
17. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors.
Gloor JM; Lager DJ; Moore SB; Pineda AA; Fidler ME; Larson TS; Grande JP; Schwab TR; Griffin MD; Prieto M; Nyberg SL; Velosa JA; Textor SC; Platt JL; Stegall MD
Transplantation; 2003 Apr; 75(7):971-7. PubMed ID: 12698082
[TBL] [Abstract][Full Text] [Related]
18. ABO-incompatible kidney transplantation in elderly patients over 60 years of age.
Uchida J; Iwai T; Machida Y; Kuwabara N; Kabei K; Murao M; Otoshi T; Naganuma T; Kumada N; Nakatani T
Int Urol Nephrol; 2012 Oct; 44(5):1563-70. PubMed ID: 22828739
[TBL] [Abstract][Full Text] [Related]
19. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
Sawada T; Fuchinoue S; Teraoka S
Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
[TBL] [Abstract][Full Text] [Related]
20. Double-filtration plasmapheresis.
Tanabe K
Transplantation; 2007 Dec; 84(12 Suppl):S30-2. PubMed ID: 18162985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
